



Express Mail Label No. EL5852463101
Date of Deposit: June 21, 2001

PATENT

Attorney Docket No: 15966-703 (CURA-203)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:	Not Yet Assigned
APPLICANTS:	Padigaru, et al.
SERIAL NO:	09/800,321
FILING DATE:	March 5, 2001
FOR :	NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (2 pages);
- ☒ Form PTO-1449 (submitted in duplicate; 3 pages);
- ☒ Copy of the cited references, C1-C53; and
- ☒ Return postcard

If the enclosed papers are considered incomplete, the Mail Room or the Application Branch is respectfully requested to contact the undersigned at 617 542-6000.

If any additional fees are to be assessed, the Commissioner is hereby authorized to charge the balance due to the undersigned's account, Deposit Account No. 50-0311, Reference 15966-703 (CURA-203). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi (Reg. No. 39,529)

Christina V. Karnakis (Reg. No. 45,899)

Attorneys for Applicants

c/o MINTZ LEVIN, COHN, FERRIS,

GLOVSKY AND POPEO P.C.

One Financial Center

Boston, Massachusetts 02111

Telephone: (617) 542-6000

Telefax: (617) 542-2241

Express Mail Label No.: EL585246310US

Date of Deposit: June 21, 2001



PATENT
Attorney Docket No: 15966-703 (CURA-203)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT: Not Yet Assigned
APPLICANTS: Padigaru et al.
SERIAL NO: 09/800,321
FILING DATE: March 5, 2001
FOR : NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

June 21, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97, and 1.98, Applicants hereby make of record the attached documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

- ☐ This Information Disclosure Statement is being been filed:
within three months of the filing date of the National Application;
☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the


APPLICANTS: Padigaru et al.

present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 15966-703 (CURA-203)).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina V. Karnakis, Reg. No. 45,899

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRA1531753v1